May 13 2019 09:34 AM

Boehringer Ingelheim Seeks 2019 Producers for Progress Applicants

The information below has been supplied by dairy marketers and other industry organizations. It has not been edited, verified or endorsed by Hoard’s Dairyman.

Boehringer Ingelheim (BI) is once again accepting applications for its Producers for Progress Recognition Program. The program honors those who have demonstrated commitment to the well-being of their animals through the judicious use of antibiotics.

Applications are due Monday, July 1, 2019, and can be found at or by contacting your BI representative.

The top producer, as determined by a panel of industry-expert judges, will receive the grand prize of a John Deere® Gator™ Basic Package XUV825E and an all-expenses-paid trip to the 2019 World Dairy Expo; the first-place-prize recipient wins five pairs of Bogs® Rancher boots from Bogs® Footwear; and an additional second-place winner will receive 10 Udder Tech® milking aprons.

The 2018 grand prize winner, Jami Schultze of Maple Ridge Dairy in Stratford, Wisconsin, shares her perspective on judicious antibiotic use: “Consumers are concerned about their food more than ever now. As a dairy farm, it is our job to build trust and be transparent to the consumer, and actively show them we have nothing to hide. If our industry does not continue to improve and show responsible antibiotic usage, we risk having further regulations forced upon us.”

Schultze demonstrates a strong commitment to the future of the dairy industry, and BI aims to continue rewarding those producers going above and beyond to care for their animals through the Producers for Progress Recognition Program.

Application information

Applicants will be asked to answer a few open-ended questions about their preventive management practices, their views on judicious use of antibiotics, and to describe their mastitis treatment protocols.

Three dairy producers will then be selected by the judges to receive the Producers for Progress recognition, based on the following criteria:

  • Demonstrated understanding of and passion for judicious use of antibiotics;
  • Commitment to animal well-being; and
  • Being a customer of at least one BI mastitis product.

Applicant names and operations will remain anonymous during judging. Prize recipients will be selected and notified by Thursday, August 15, 2019.

Are you or is someone you know deserving of Producers for Progress recognition? Apply by visiting to fill out the online application form, or contact your local BI representative. Applications are due July 1, 2019.

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 percent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success rather than short-term profit. The company therefore aims at organic growth from its own resources, with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility toward mankind and the environment.

More information about Boehringer Ingelheim can be found at or in our annual report:

About Boehringer Ingelheim Animal Health

Boehringer Ingelheim is the second largest animal health business in the world. We are committed to creating animal wellbeing through our large portfolio of advanced, preventive healthcare products and services. With net sales in 2017 of 3.9 billion euros ($4.4 billion) and around 10,000 employees worldwide, we are present in more than 150 markets. For more information, visit here: